Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Gastro-enteropancreatic neuroendocrine tumor × cabozantinib × 90 days × Clear all

Sponsor

Conditions

Carcinoma, Renal Cell 25 Carcinoma, Hepatocellular 4 Urinary Bladder Neoplasms 3 Urethral Neoplasms 3 Prostatic Neoplasms 3 Osteosarcoma 3 Melanoma 3 Kidney Neoplasms 3 Colorectal Neoplasms 3 Clear-cell metastatic renal cell carcinoma 3 Urogenital Neoplasms 2 Ureteral Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Small Cell Lung Carcinoma 2 Sarcoma, Ewing 2 Penile Neoplasms 2 Ovarian Neoplasms 2 Neuroendocrine Tumors 2 Neoplasm Metastasis 2 Carcinoma, Transitional Cell 2 Carcinoma, Non-Small-Cell Lung 2 Carcinoma 2 Brain Neoplasms 2 Adrenocortical Carcinoma 2 von Hippel-Lindau Disease 1 Urologic Neoplasms 1 Urachal adenocarcinoma 1 Triple Negative Breast Neoplasms 1 Seminoma 1 Sarcoma, Kaposi 1

Interventions

lutetium Lu 177 dotatate 3 pasireotide 2 Octreotide 2 lanreotide 1 copper dotatate CU-64 1 abemaciclib 1 Sunitinib 1 Receptor-Like Protein Tyrosine Phosphatases, Class 2 1 Lutetium-177 1 Lutetium 1 Everolimus 1 E-7386 1 Cryotherapy 1 Acupuncture Therapy 1 Acupressure 1 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡